Summary of Medical Services Industry Conference Call Industry Overview - The medical services industry experienced a slight revenue increase of 0.2% to 36 billion in the first half of 2024, with a decline in the second quarter due to high base effects from the previous year [1][2] - Consumer medical services, particularly in ophthalmology, showed resilience, while serious medical service companies faced a revenue decline of 15%-20% due to high base effects and DRG/DIP consulting fees [1][4] Key Insights and Arguments - **Ophthalmology Sector Performance**: - Aier Eye Hospital's refractive and optical businesses achieved double-digit growth, leading the industry [1][5] - Other companies in the cataract business experienced declines due to the impact of crystal procurement, but a recovery is expected in the second half of the year [1][5] - The price war in refractive services is diminishing, and the demand for optical services is expected to rise due to the conclusion of the youth myopia prevention plan [1][5][8] - **Medicare Policy Impact**: - From January to July, the Medicare fund showed stable income growth of 7% and a spending decrease of 1%, indicating pressure on the expenditure side [9] - Data from cities like Chongqing, Tianjin, and Guangxi suggest steady outpatient visits, with expectations for recovery in demand and reporting in the second half of the year [9] - **Aier Eye Hospital's Strategic Expansion**: - The company aims to increase its overseas market share from the current 10-15% to 30-50% [1][10] - New business opportunities include advanced refractive procedures, multi-focus cataract upgrades, and presbyopia surgeries, with AI technology expected to enhance operational efficiency [1][10] Company-Specific Performance - **Aier Eye Hospital**: - Reported a 9% revenue growth and a 14% increase in net profit excluding non-recurring items in the first half of 2024 [3][8] - The average selling price (ASP) in refractive services increased by approximately 5% [5][8] - **International Medical**: - Faced operational pressure with a 16% revenue decline but managed to reduce net profit loss by 15% through improved diagnostic efficiency and optimized inpatient services [3][11] - The proton center is set to commence operations, and the aesthetic medical business is expected to grow significantly [11] Future Development Expectations - The second half of 2024 is anticipated to show optimistic trends for the medical services industry, with potential stock price opportunities due to accelerated company performance [3][12] - Policy changes, such as the introduction of provincial payment details and the expansion of prepayment and real-time settlement, are expected to positively impact the industry [12][13] - The overall beta slope of the industry is expected to improve, indicating a recovery in company performance and elasticity [13]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights an increase in the average revenue per customer in the refractive surgery segment and emphasizes the importance of promoting new surgical techniques, organizational changes, and overseas expansion [1][8] - The company achieved a total revenue of 11.507 billion yuan in H1 2025, reflecting a year-on-year growth of 9.12%, while the net profit attributable to shareholders was 2.051 billion yuan, a slight increase of 0.05% [8] - The report anticipates continued growth in the ophthalmology sector, driven by the release of consumer demand and the company's strategic initiatives [8] Financial Forecasts - Total revenue projections for the company are as follows: 20.367 billion yuan in 2023, 20.983 billion yuan in 2024, 23.579 billion yuan in 2025, 26.302 billion yuan in 2026, and 29.124 billion yuan in 2027, with year-on-year growth rates of 26.43%, 3.02%, 12.37%, 11.55%, and 10.73% respectively [1] - The net profit attributable to shareholders is forecasted to be 3.359 billion yuan in 2023, 3.556 billion yuan in 2024, 4.098 billion yuan in 2025, 4.680 billion yuan in 2026, and 5.350 billion yuan in 2027, with corresponding growth rates of 33.07%, 5.87%, 15.25%, 14.19%, and 14.32% [1] - The report projects the earnings per share (EPS) to be 0.36 yuan in 2023, 0.38 yuan in 2024, 0.44 yuan in 2025, 0.50 yuan in 2026, and 0.57 yuan in 2027 [1] Operational Insights - The company has seen a rapid increase in patient volume, with outpatient visits reaching 9.248 million in H1 2025, a growth of 16.47%, and surgical procedures totaling 879,000, an increase of 7.63% [8] - The refractive surgery segment has benefited from the introduction of new equipment, leading to a rise in average revenue per customer and a reversal of previous price competition trends [8] - The company is also focusing on expanding its services for presbyopia treatment and enhancing its AI applications in ophthalmology [8]

Core Viewpoint - The company reported its 2025 H1 financial results, showing a revenue of 11.507 billion yuan (+9.12% year-on-year) and a net profit attributable to shareholders of 2.051 billion yuan (+0.05%) [1] Financial Performance - In 2025 H1, the company achieved a net cash flow from operating activities of 3.4 billion yuan (+20%) [1] - The Q2 2025 revenue was 5.481 billion yuan (+2.47%), with a net profit of 1.001 billion yuan (-12.97%) [1] - The outpatient volume reached 9.248 million visits (+16.47%), and the number of surgeries performed was 879,000 (+7.63%) [1] Business Segments - The refractive business saw an increase in average transaction price due to the introduction of new equipment, reversing the trend of price competition [2] - The cataract business growth was driven by an increase in the number of surgeries, despite a 7.57% year-on-year decline in surgery unit price due to policy impacts [2] - The company is accelerating the integration of AI in ophthalmology, having consolidated 28 high-quality ophthalmology specialty data sets [2] Organizational Changes - The company established a leadership group for organizational change in January 2025 to enhance operational efficiency [2] - Adjustments in the organizational structure aim to promote development in advantageous provinces and optimize management across multiple hospitals [2] Profit Forecast and Investment Rating - The company maintains profit forecasts for 2025-2027 at 4.098 billion, 4.680 billion, and 5.350 billion yuan, corresponding to PE ratios of 30, 26, and 23 times [3] - The ophthalmology medical industry is expected to have good growth potential as consumer demand continues to be released, maintaining a "buy" rating [3]

每经AI快讯，有投资者在投资者互动平台提问：目前针对老年人的视力矫正并不普及，很多人觉得老 花眼没办法治疗，公司有没有关注到这方面的潜在需求，在这方面有没有相关的技术储备，公司的技术 储备在国际上处于什么样的水平？ 爱尔眼科（300015.SZ）8月18日在投资者互动平台表示，目前国内大多数中老年人对老花（老视）治疗 的认知程度不高，老花治疗在国内普及率极低，还处于启蒙阶段。 与之对应的是，欧洲地区对老花治 疗的接受度较高，公司的欧洲子公司经验丰富，老花手术业务发展良好。为了适应人口老龄化背景下的 大量新需求，公司结合海外团队经验积极发展老年眼病诊断、老视治疗等业务，已在多地爱尔医院开设 老视门诊，并将成立老视学组，为广大中老年人群提供适宜的视觉解决方案。 随着适龄段人群支付能 力的提高和对视觉品质的追求，老花诊疗未来有望持续增长。 （文章来源：每日经济新闻） ...